A Study to Evaluate the Effect of IMB-1018972 on Cardiac Energetics in Patients With Type 2 Diabetes (IMPROVE-DiCE)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetic Cardiomyopathies
- Type 2 Diabetes
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04826159
- Collaborators
- University of Oxford
- Investigators
- Study Director: Paul Chamberlin, MD Imbria Pharmaceuticals, Inc.